---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-013672"
form_type: "8-K"
ticker: "PSTV"
cik: "0001095981"
company_name: "PLUS THERAPEUTICS, INC."
filed_at: "2023-04-20T23:59:59+00:00"
generated_at: "2026-06-16T22:10:20.447620+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Plus Therapeutics Q1 2023 net loss $4.8M, cash $12.7M; completes ReSPECT-LM Phase 1/Part A

## Summary
- Completed Part A of ReSPECT-LM Phase 1/2a dose escalation trial for rhenium obisbemeda in leptomeningeal metastases.
- Q1 cash $12.7M vs $18.1M at Dec 31, 2022; net loss $0.14/share vs $0.19 prior year.
- Operating expenses $5.2M, up from $3.9M YoY, driven by $750K milestone payment to NanoTx Corp and clinical enrollment.
- Grant revenue $506K from CPRIT; total grant awards of $20.6M from NIH and CPRIT.
- Expects to present ReSPECT-GBM and LM data in H2 2023; planning to initiate pediatric trial.

## SEC filing metadata
- accession: 0000950170-23-013672
- form_type: 8-K
- ticker: PSTV
- cik: 0001095981
- company_name: PLUS THERAPEUTICS, INC.
- filed_at: 2023-04-20T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1095981/000095017023013672/0000950170-23-013672-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1095981/000095017023013672/pstv-20230420.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-013672
- JSON: https://secwatch.observer/filing/0000950170-23-013672.json
- Plain text: https://secwatch.observer/filing/0000950170-23-013672.txt

## Key facts
- Earnings Releases
  PLUS THERAPEUTICS, INC. reported first quarter ended March 31, 2023 results: revenue $506,000, net income $4.8 million, EPS $(0.14) per share.
  - Period: first quarter ended March 31, 2023
  - Revenue: $506,000
  - Net income: $4.8 million
  - EPS: $(0.14) per share
  - Result: reported results
  source text: FIRST QUARTER 2023 FINANCIAL RESULTS ▪ The Company’s cash balance was $12.7 million at March 31, 2023, compared to $18.1 million at December 31, 2022. ▪ The Company recognized $506,000 of grant revenue in the first quarter of 2023, which represents the Cancer Prevention & Research Institute of Texas’ (CPRIT) share of costs incurred in the development of rhenium
  evidence_url: https://www.sec.gov/Archives/edgar/data/1095981/000095017023013672/0000950170-23-013672-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.